Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells $16,875,000.00 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 75,000 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director owned 31,596 shares in the company, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $230.59 on Friday. The stock has a 50-day simple moving average of $181.50 and a 200-day simple moving average of $184.67. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The stock has a market capitalization of $11.11 billion, a PE ratio of -61.33, a PEG ratio of 2.63 and a beta of 1.40. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $236.62.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of analyst reports. Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. Barclays boosted their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a report on Wednesday. CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and raised their price target for the company from $167.00 to $219.00 in a research note on Friday, May 29th. Finally, Morgan Stanley raised Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $185.00 to $220.00 in a research report on Wednesday, June 17th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.88.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Hilltop National Bank grew its position in shares of Charles River Laboratories International by 28.7% in the 2nd quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock valued at $129,000 after buying an additional 127 shares during the last quarter. NewEdge Advisors LLC lifted its position in Charles River Laboratories International by 1,119.5% in the first quarter. NewEdge Advisors LLC now owns 3,195 shares of the medical research company’s stock valued at $551,000 after acquiring an additional 2,933 shares during the last quarter. Avidity Partners Management LP purchased a new stake in Charles River Laboratories International in the first quarter valued at $1,670,000. Glenmede Trust Co. NA boosted its stake in Charles River Laboratories International by 2.8% in the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after acquiring an additional 73 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after acquiring an additional 54,500 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.